Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis

• Status: Active, not recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the efficacy, safety and pharmacokinetics (PK) of VX-147 in subjects with apolipoprotein L1 (APOL1)-mediated focal segmental glomerulosclerosis (FSGS).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Vertex Pharmaceuticals Incorporated

Criteria

Key Inclusion Criteria:

• APOL1 genotype of G1/G1, G2/G2, or G1/G2

• FSGS diagnosed by kidney biopsy

Key Exclusion Criteria:

• Evidence of non-APOL1-mediated FSGS

• Subjects with known sickle cell disease

• Solid organ or Bone marrow transplant

Other protocol defined Inclusion/Exclusion criteria may apply.